Preservative-Free Microemulsion for Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic compositions for treating dry eye syndrome often contain irritating ionic surfactants and preservatives, leading to potential eye irritation and low patient compliance, while existing treatments with active agents like cyclosporine A or lifitegrast may cause side effects and have limited long-term efficacy.
Innovation Solution
A microemulsion comprising an oily component, an aqueous phase, a non-ionic surfactant, a polysaccharide, and a cross-linking agent, which avoids the use of ionic compounds and preservatives, providing improved shelf-life, wetting, and ocular tolerability, and is free from harmful ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If ionic surfactants and preservatives are used in ophthalmic compositions, then emulsion stability and shelf-life are improved, but eye irritation and harmful effects increase
Solution Approach 1:
The patent removes ionic surfactants and preservatives from the ophthalmic composition, extracting the harmful components while maintaining the therapeutic function through alternative non-ionic surfactant systems
Solution Approach 2:
The patent introduces non-ionic surfactants as intermediary substances that provide the necessary emulsion stability and shelf-life without causing eye irritation, serving as a safe mediator between the oily and aqueous phases
2Reliability
If active agents like cyclosporine A or lifitegrast are used for severe DES treatment, then treatment efficacy is improved, but side effects and low patient compliance increase
Solution Approach 1:
The patent employs a simple, preservative-free microemulsion formulation that can be used frequently without accumulating harmful effects, replacing long-term drug therapy with a safer, repeatable topical application
Solution Approach 2:
The patent changes the physical state and delivery mechanism of therapeutic components by using a microemulsion system with optimized droplet size and composition, improving penetration and efficacy while reducing the need for high-dose pharmaceutical agents
3Ease of operation
If conventional emulsions are used for dry eye treatment, then basic lubrication is provided, but wetting properties and ocular tolerability are insufficient
Solution Approach 1:
The patent creates a composite microemulsion system combining oily components, aqueous phase, non-ionic surfactants, and polysaccharides in specific ratios, achieving superior wetting properties and ocular tolerability that individual components cannot provide alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microemulsion effectively treats dry eye syndrome by enhancing tear film reconstruction, reducing water evaporation, and lubricating the ocular surface, while maintaining stability and avoiding eye irritation, thus offering a more tolerable and effective treatment option compared to existing formulations.
Implementation Method 1
at least one non-ionic surfactant
Implementation Method 2
at least one cross-linking agent
Implementation Method 3
improved shelf-life
Implementation Method 4
reducing water evaporation
Data Source
AI summary
The present invention refers to a microemulsion, particularly suitable for ophthalmic applications such as treatment of dry eye syndrome, which comprises at least one oily component, an aqueous phase, at least one non-ionic surfactant, at least one polysaccharide, a salt or a derivative thereof, and at least one cross-linking agent. Moreover, the present invention relates to a process of manufacturing a microemulsion according to the invention, as well as its use in ophthalmic applications or as a carrier.